Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
linifanib
- Development stage
- Phase 3
- Lead developer
- Abbott
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Linifanib is an orally active, small molecule multi-targeted receptor tyrosine kinase inhibitor. It potently inhibits all members of the vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptor families, as well as FLT3 and KIT kinases. By blocking these pathways, linifanib suppresses tumor angiogenesis and proliferation. Linifanib was investigated in clinical trials for several solid tumors and hematologic malignancies. It was developed by Abbott Laboratories/AbbVie.
- Other names
- 1-(4-(3-amino-1H-indazol-4-yl)phenyl)-3-(2-fluoro-5-methylphenyl)urea
02
Targets
VEGFR-1 (Vascular endothelial growth factor receptor 1)FLT3 (Fms related receptor tyrosine kinase 3)CSF1R (Macrophage colony-stimulating factor receptor)PDGFRB (Platelet-derived growth factor receptor beta)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on linifanib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on linifanib.